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ABSTRACT
Objectives: Recent advances in monoclonal antibody therapies offer the
prospect of the prevention or amelioration of type 1 diabetes mellitus
(T1DM). The present study was designed to capture UK (English and
Scottish) preference weights for the process of undergoing infusion therapy
and the likely outcomes of treatment for children (8–12 years), adolescents
(13–17 years), and adults.
Methods: Vignette descriptions of T1DM health states (describing
infusion therapy and reduced insulin need) were constructed based on
qualitative interviews with people with type 1 diabetes, clinicians and
ﬁndings from a literature review. Utilities were elicited for each health
state using the standard gamble interview from the general public, adults
with diabetes, and parents of children with diabetes. Participants also
completed other outcome measures—EQ-5D, Pediatric Quality-of-
Life Inventory, and Hyperglycemic Fear Survey. Mixed model analyses
were used to estimate the inﬂuence on utility of different participant
characteristics.
Results: Self-report questionnaires indicated the nature and degree of
impact of T1DM on adults’, adolescents’, and children’s quality of life,
with adolescents reporting the lowest health-related quality-of-life proﬁle
of all groups. The mixed model analysis indicated that each health state
was a signiﬁcant predictor of utility and the T1DM participants gave
signiﬁcantly higher utilities compared with the general public (P = 0.02).
Conclusion: The general public and people with diabetes (or parents of
children with diabetes) all place signiﬁcant value on reducing the need for
insulin injections; also, all recognize the disutility of undergoing infusion
cycles. These values are suitable for supporting estimates of cost-
effectiveness of infusion therapies in T1DM.
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Introduction
Type 1 diabetes mellitus (T1DM) leaves people unable to
produce insulin. As a result, patients and their carers are left to
manage the disease through a combination of a carefully calcu-
lated diet, planned physical activity, repeated blood glucose
testing, and multiple daily insulin injections. Even with strict
glycemic control measures, patients face the risk of serious com-
plications including cardiovascular disease, diabetic retinopathy,
neuropathy, and nephropathy [1,2]. T1DM has a signiﬁcant
impact on health-related quality of life (HRQL) of patients in
terms of both the management of the disease and the impact of
complications [3].
Recent advances in anti-CD3 monoclonal antibody-based
therapy offer the prospect of a treatment that may modulate the
autoimmune response that leads to the destruction of the beta
cells of the islet cells in the pancreas, and thus preserve their
function [4]. In turn, this should signiﬁcantly improve glycemic
control in individuals undergoing therapy. The Food and Drug
Administration [5] recognizes the evidence from the Diabetes
Control and Complications Trial (DCCT) and other studies that
have demonstrated clinical beneﬁts in patients who achieve better
glucose control, in terms of delaying the chronic complications of
diabetes [1]. It is established that greater preservation of endog-
enous insulin secretory function (as assessed by C-peptide in the
serum) is associated with lower HbA1c and fewer hypoglycemic
events over time [5].
Maintaining good glycemic control will lead to better quality
of life for people with diabetes [6]. This can be measured through
the use of standardized surveys and such data can help to inform
patient decision-making. Increasing data regarding HRQL are
also used to guide centralized decision-making by health-care
providers and health technology assessment agencies such as the
UK’s National Institute for Health and Clinical Excellence [7].
HRQL data have become a key component of economic evalua-
tions because the data are used in weight survival in the estimation
of quality-adjusted life-years (QALYs). Many agencies, including
NICE, prefer to see these weights (or utilities) regarding the value
of a health state to be derived from interviews with the general
public using standardized methodologies. Nevertheless, others
have argued that only patients really have insight into the effects of
a disease and so their views should be considered too [8].
The present study was designed to capture utility weights
from people with T1DM, parents of children and adolescents
with T1DM, and the UK general public in terms of both the
beneﬁts and burden of undergoing infusion-based therapies. In
addition, other data were collected to better understand the
HRQL proﬁle of these different groups of participants.
Methods
This study was designed to capture utilities by presenting par-
ticipants with vignette descriptions of health and HRQL and
asking them to rate each vignette in the standard gamble task.
The vignettes were developed based on literature review and on
in-depth interviews with patients, parents, and clinicians. We
collected utility values for three distinct age categories, adults
with T1DM, adolescents with T1DM, and children with T1DM.
Literature Review
A literature search was conducted reviewing articles published in
the English language between the years 2000 and 2008
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(restricted time period because of change in insulin therapy in
recent years). The search was designed to identify primarily
qualitative articles which were informative regarding the nature
of the impact of T1DM on HRQL. From 604 abstracts reviewed,
28 were identiﬁed for full review (on the basis that these provided
detailed information on a broad spectrum of relevant concerns).
A detailed review or summary of these studies is beyond the
scope of this article. The review identiﬁed a number of factors
that affect HRQL in adolescents and younger children with
T1DM.
Several studies identiﬁed how adolescents and children with
T1DM experience problems concerning treatment, difﬁculties in
social and daily life, as well as a negative mental attitude con-
cerning diabetes [9]. Long-term complications, poor psychologi-
cal well-being, and fear of hypoglycemia were also all identiﬁed
as affecting the HRQL of people [10]. These issues can have a
particularly marked effect on HRQL in young adults because of
effects on socializing and mobility. During adolescence, the “con-
stant attendance” of the disease, limits on behavior, and the high
number of therapy administrations can lead to deterioration in a
patient’s quality of life [11]. Many studies have also reported
how T1DM produces a signiﬁcant degree of psychological dis-
tress including depression [12]. Nevertheless, other studies
suggest that the burden of diabetes in adolescents is not substan-
tial when their HRQL and psychological status are compared to
other adolescents [13,14].
Glycemic control has been shown to affect different aspects of
HRQL. People with higher HbA1c reported more worry and
worse overall health perception in one study by Vanelli et al.
[15]. Poor glycemic control in T1DM has been shown to be
associated with depression, greater worry, poorer health percep-
tion, and poor HRQL [16–20].
Some work has also explored the burden of the need to
manage blood sugar levels [12,21]. In addition, Nordfeldt and
Ludvigsson [22] describe the fear of severe hypoglycemia
reported by children and adolescents with T1DM. Severe
hypoglycemia was viewed as a serious problem, regardless of
whether a recent event had occurred. Participants reported how
severe hypoglycemia disrupted certain activities, such as exercise,
discos or parties, and travel situations.
Patient and Clinician Interviews
To further assess the impact of T1DM on different aspects of
HRQL, 12 in-depth face-to-face interviews were conducted with
individuals who had direct experience of dealing with the con-
dition (four adults with T1DM, four parents of adolescents with
T1DM aged 13–17 years, and four parents of children with
T1DM aged 8–12 years).
A discussion guide was developed using the ﬁndings from
the literature review. The semistructured interviews were
designed to explore different aspects of HRQL. A thematic
analysis [23] was conducted using the qualitative analysis soft-
ware tool, ATLAS.ti (v5.0) (Scientiﬁc Soft, Berlin, Germany).
The data were analyzed to describe some themes that had
already been identiﬁed (e.g., physical functioning, psychological
functioning) and also to identify additional themes if possible.
To expand the perspective of the analysis, interviews were
also completed with a consultant endocrinologist, a diabetolo-
gist, and a diabetes specialist nurse. The experts were encouraged
to provide their perspective on the likely impact of T1DM for
patients of varying ages and to relay their experiences of clinical
practice with the patient group.
Findings from the patient and clinician interviews were very
consistent. The impact of T1DM was described as pervasive and
inescapable for those with the condition. The necessity for con-
stant monitoring, insulin injections, and enforced dietary restric-
tion was seen as a constant and lifelong burden. The concerns of
patients reﬂected worries about the potential for developing com-
plications, the fear of hypoglycemic events, and the burden of
managing the condition. Also, clinicians described the impor-
tance of good glycemic control in maintaining HRQL.
Health State Development and Piloting
Short vignette descriptions of health and HRQL were produced
based on the interviews and literature review (Appendix A). The
health states were designed to cover the key elements of HRQL
by describing different areas of functioning (speciﬁcally physical,
psychological, and social functioning), symptoms, usual activi-
ties, and work. Five adult states (aged 18–35 years) were devel-
oped which described a normal baseline T1DM state, one T1DM
state with reduced need for insulin injections, one T1DM state
which was insulin-free, and two states that described infusion
therapies (one with an associated acute phase reaction). Also, a
worst and full health state was developed to be able to complete
the standard gamble task. Parallel states were also developed
describing adolescents (13–17 years) and younger children (8–12
years). The health states do not make explicit reference to T1DM
as it was felt that this may potentially bias how people value
them. This can be seen at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i5_Lloyd.asp.
The draft health states underwent a content validity review by
two consultant endocrinologists, two diabetes specialist nurses,
an adult with T1DM, and the parent of an adolescent with
T1DM to assess accuracy and appropriateness of language. Sug-
gested changes to the wording of the health states were incorpo-
rated. The health states were then piloted with four participants
in a valuation and cognitive debrieﬁng interview to check that
they were clear and would be understood by the general public.
Further small revisions to the wording were made.
A larger pilot study was undertaken to test people’s ability to
rate the health states. Twelve members of the general public
completed the visual analog scale (VAS) exercise, standard
gamble interview, and a cognitive debrieﬁng exercise. No further
issues were identiﬁed from these interviews.
Valuation Study
The health states were included in a UK-based valuation
exercise to estimate utilities. Members of the UK general
public (n = 100) were recruited through regional advertising
in four areas (Oxford, Reading, Leamington Spa, and Stirling).
Adults with T1DM (aged 18–35 years; n = 36 in England,
n = 15 in Scotland) and 44 parents of children suffering from
diabetes (n = 36 in England, n = 8 in Scotland) were recruited
through a specialist patient recruitment agency. The parents
group only included parents of children with T1DM under the
age of 18 years. All interviews were conducted by four trained
interviewers.
All participants provided written informed consent and com-
pleted a sociodemographic questionnaire. In addition, other
outcome measures were administered to try and characterize the
nature and extent of the burden of T1DM—the EQ-5D (proxy
version was completed by parents), the Hypoglycemia Fear
Survey (T1DM adults only), the Pediatric Quality-of-Life Inven-
tory (PedsQL), and PedsQL diabetes speciﬁc module (completed
by parents only). The EQ-5D is a generic HRQL measure which
includes ﬁve domains (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) and a VAS for self-rated
health [24,25]. Responses were scored using the UK preference
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weights to estimate utilities [26]. The Hypoglycemic Fear Survey
(HFS) includes two domains with 5-point scales, Behavior (10
items with higher scores indicating more cautious behavior) and
Worry (18 items with higher scores indicating increased concern
about experiencing a hypoglycemic event) [27]. The PedsQL used
in the present study included the core scales of Physical Func-
tioning (eight items), Emotional Functioning (ﬁve items), Social
Functioning (ﬁve items), and School Functioning (ﬁve items) plus
two summary scores (Psychosocial Health Summary Score and
Physical Health Summary Score). Additionally, it included a dia-
betes speciﬁc module with ﬁve subscales including Diabetes (11
items), Treatment I (four items), Treatment II (seven items),
Worry (three items), and Communication (three items). All
survey items are scored on a 5-point scale with higher scores
indicating greater experience of problems.
The valuation interview included a VAS task and the Stan-
dard Gamble (SG) exercise. Before completing the SG task, par-
ticipants rated each health state on the VAS, which had a
lowest anchor value of 0 (dead) and a highest anchor value of
100 (full health). Participants were permitted to alter their
answers until satisﬁed that the rankings accurately reﬂected his/
her preferences.
Participants were administered the SG task for the same set of
health states. The general public and adults with T1DM assessed
the adult T1DM states, and the parents assessed the adolescent
or child states (dependent on the age of their child with T1DM).
SG is the conventional gold standard method for eliciting pref-
erences for health states because it involves making a choice
under conditions of uncertainty [28]. Participants are presented
with the certain Choice A (remaining in the selected health state)
or the risky prospect (Choice B), which is a gamble involving a
probability (P) of achieving full health versus a corresponding
probability (1-P) of ending up in the “worst health” (a hypo-
thetical very severe state). The probability P is varied (using
alternate high and low values) until the respondent is indifferent
between Choice A and Choice B. The “worst health” state is then
compared with either the prospect of full health or death to
rescale responses to the other states onto a dead (0) to full health
(1.0) scale. Visual props (i.e., a ﬂip book with pie charts) and
experienced interviewers were used to elicit utility values for each
health state. All participants were offered £25 to compensate
them for their time.
Statistical Analyses
All surveys were scored according to the developers instructions.
The SG data were rescaled against dead so that all utilities were
on a 0–1.0 scale. All analyses were described a priori in the
statistical analysis plan. Between groups, comparisons were
based on nonparametric Student Newman–Keuls test for inde-
pendent groups or independent samples t-test for parametric
data.
SG data were transformed (inverted logistic transformation)
to achieve more normally distributed data. Mixed models were
ﬁtted using SAS, version 9.1 (SAS Institute Inc., Cary, NC) using
the SAS mixed procedure. S-PLUS, version 7.0 (Tibco Soft, Palo
Alto, CA) was also used for some analyses. Health state, diabetes
status, and age group were entered into the model, whereas sex,
education, occupation, and EQ-5D VAS were inspected as poten-
tial covariates. The base model was a linear mixed model with a
random intercept by patient. A model was ﬁt with all covariates
and the likelihood ratio of this model was compared, in turn, to
models with each of these variables removed one at a time using
the likelihood ratio test (LRT). Final models were estimated using
Restricted Maximum Likelihood test.
Once important covariates were identiﬁed, an LRT was done
to check if the random effects were consistent with the data.
Different covariance matrices were also tested. The need for a
random coefﬁcient model, i.e., a random slope effect for the SG
values over the different health states, was also tested by the LRT.
Results
Participant Characteristics
The general public and adult T1DM patient background data are
presented in Tables 1 and 2. The societal sample was a relatively
good match to the UK Census data (ONS, 2001).
Participants’ Quality-of-Life Data
The PedsQL data are presented to contrast the older and younger
children in the sample (Table 3). Some small differences exist
between the two groups of participants, but these are not signiﬁ-
cant (where data was nonnormally distributed, nonparametric
analysis conﬁrmed these results).
Table 1 Participant demographic characteristics for the general public and adult patient groups
Adult T1DM (N = 51) General public (N = 100) UK Census and ONS data
Age—mean (standard deviation) 27.55 43.04 (12.4) 38.2
Sex—male (% male) 29 (56.9%) 39 (39%) 49%
Ethnic group
Asian or Asian British 3 (5.9%) 3 (3.0%) 4.0%
Black or British black 2 (3.9%) — 2.0%
White 45 (88.2%) 92 (92.0%) 92.1%
Other (including mixed race) 1 (2.0%) 5 (5.0%) 1.9%
Employment status
Full time 27 (52.9%) 44 (44.0%) Full & Part Time
43.6%Part time 7 (13.7%) 20 (20.0%)
Student 9 (17.6%) 10 (10.0%) 1.9%
Unemployed/seeking work 4 (7.9%) 6 (6.0%) 4.8%
Retired 1 (2.0%) 5 (5.0%) 9.8%
Stay at home 1 (2.0%) 3 (3.0%) 4.6%
Other 2 (3.9%) 12 (12.0%) 2.3%
Education—leaving age
Left school with no qualiﬁcations 1 (2.0%) 7 (7.0%) n/a
Left school at 16 with qualiﬁcations 9 (17.6%) 19 (19.0%) n/a
Stayed on at school/college to gain further qualiﬁcations 30 (58.8%) 26 (26.0%) n/a
University level 11 (21.6%) 48 (48.0%) n/a
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The EQ-5D was collected for all study participants (Table 4).
Scores for adults with T1DM and for the general public were
self-reported. These data show some differences between people
suffering from diabetes and the general population. The data for
the child and adolescent groups were rated by their parents.
There is some evidence of a relative decline in scores for the
adolescent group and post hoc testing does reveal signiﬁcant
differences between groups on EQ-5D single index score.
The Hypoglycemia Fear Survey is available for adults with
T1DM only. Mean (standard deviation) scores for Behavior and
Worry subscales were 21.5 (5.3) and 22.3 (12.0), respectively.
Health State Utility Values for Infusion Therapy
Analyses of the utilities from the SG interviews revealed that
diabetes status was the only signiﬁcant predictor of the SG utility
(P = 0.02). Age group was retained in the model because it was
an important predictor by design and was needed to estimate
mean SG utility by age group. The LRT comparing the mixed
model with a random intercept effect to one without random
effects indicated that a random intercept for patient was impor-
tant for the model (LRT = 465.0, 1 + df, P < 0.001). There was
no evidence for the need for a random slope for the different
health states (LRT = 1.81, 2 + df, P = 0.40).
The LRT comparing the unstructured covariance matrix with
the compound symmetry matrix indicates that the unstructured
matrix was signiﬁcantly better than compound symmetry
(LRT = 320.5, 13 + df, P < 0.001). Utilities for each state were
estimated from the model (Table 5).
Finally, data from English and Scottish participants were
compared to explore the similarities in their preference weights
(Table 6). This summary shows that the utilities were very similar
albeit that the Scottish sample was small in some subgroups.
Discussion
The aim of this study was to capture utilities for health states
that describe infusion therapy for the treatment of T1DM.
Quantifying the potential impact of undergoing infusion
therapy (both in terms of possible treatment outcomes and
associated burden) is a valuable exercise in its own right and
these data will also be suitable for supporting decision-making
by patients, health-care providers, prescribers, and national
reimbursement agencies.
The initial literature review highlighted a number of universal
and more age-speciﬁc concerns for individuals living with diabe-
tes. Accordingly, a rigorous process was undertaken in the devel-
opment of the health states used in this study. This exercise
formed the basis for the development of a discussion guide for
use in a series of in-depth interviews with patients, with parents
of children and adolescents with T1DM, and with health-care
professionals. The interviews revealed the complex and idiosyn-
cratic nature of the impact of diabetes for individuals with dif-
ferent age group facing differing primary challenges. For children
and adolescents, the enforced dietary restriction was an impor-
tant inﬂuence on their quality of life in addition to the social
stigma attached to a diagnosis of diabetes resulting in a feeling of
“being different” to peers. For adults living with diabetes, these
two particular issues were generally of less importance. The
adults with T1DM (who were all under the age of 35 years) were
more concerned with the prospect of developing complications
associated with diabetes. These ﬁndings illustrate the importance
of identifying the impact of diabetes on people’s quality of life
Table 2 Demographic characteristics for parents of children/
adolescents with diabetes
Parents of adolescent
T1DM (N = 24)
Parent of child
T1DM (N = 20)
Children
Child’s age mean (std. dev.) 15.13 (1.58) 9.95 (1.18)
Child’s sex (% male) 12 (50%) 13 (65%)
Child’s years in education 10.33 (1.58) 4.85 (1.30)
Child’s ethnic group
Asian or Asian British 2 (8.3%) 1 (5%)
Black or British black 1 (4.2%) —
White 18 (75%) 18 (90%)
Other 3 (12.5%) 1 (5%)
Parents
Parent’s age mean (std. dev.) 43.0 (5.96) 41.45 (7.04)
Parent’s sex (% male) 4 (16.7%) 9 (45%)
Employment Status
Full time 3 (12.5%) 11 (55%)
Part time 11 (45.8%) 5 (25%)
Student — —
Unemployed/seeking work 3 (12.5%) —
Retired — 1 (5%)
Stay at home 4 (16.7%) 3 (15%)
Other 3 (12.5%) —
Parent’s ethnic group
Asian or Asian British 2 (8.3%) 1 (5%)
Black or British black 1 (4.2%) —
White 20 (83.3%) 17 (85%)
Other (including mixed race) 1 (4.2%) 2 (10%)
Table 3 Participants’ Pediatric Quality-of-Life Inventory scores by parent proxy for the two age groups. Signiﬁcance tested using independent samples
t-test
Dimension Children (8–12) (n = 20) Adolescent (13–17) (n = 24)
PCore Scales Mean SD Mean SD
Psychosocial Health Summary 64.29 16.84 65.87 14.06 n.s.
Physical Health Summary 82.30 17.69 78.99 16.45 n.s.
Physical Functioning 82.30 17.69 78.99 16.45 n.s.
Emotional Functioning 59.81 16.64 52.71 20.05 n.s.
Social Functioning 73.44 20.22 81.51 16.97 n.s.
School Functioning 59.50 21.94 63.54 18.15 n.s.
Diabetes Module
Diabetes 52.73 14.69 48.33 12.57 n.s.
Treatment I 56.88 15.30 56.77 22.34 n.s.
Treatment II 66.26 19.84 70.98 20.27 n.s.
Worry 66.67 21.46 54.51 23.95 n.s.
Communication 60.00 30.66 66.32 34.27 n.s.
Higher scores indicate increasing degree of problems experienced.
n.s., not signiﬁcant at 0.05 level.
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and understanding how issues such as age and sex can inﬂuence
this. These qualitative data allowed us to develop accurate age-
speciﬁc health state descriptions for use in the valuation exercise.
Following review, the health states were rated by members of the
general public, people with T1DM under the age of 35 years, and
parents of children and adolescents with T1DM in different areas
of the United Kingdom.
The SG utilities indicated the importance of positive treat-
ment outcomes. All participants recognized the value of people
with T1DM being able to reduce or even avoid the need for
insulin injections. The prospect of becoming “insulin-free” had a
greater signiﬁcance attached to it across all groups when com-
pared to the base disease state. Participants also recognized the
negative impact on quality of life of attending infusion therapy
and the experience of ﬂu-like symptoms that can occur after an
infusion. The utilities from the different groups were very con-
sistent with each other. There was only one area of difference
between the groups. This related to the values for infusion
therapy whereby adults with T1DM rated the impact of infusion
therapy on their HRQL as much less signiﬁcant as other groups.
This may be because adults with T1DM are very used to receiv-
ing injections. Participants were not explicitly informed that the
states described T1DM and infusions therapies for diabetes, and
no explicit link between the states (in terms of some states
describing treatment and others describing outcomes) was pre-
sented to participants. It is possible, however, that the adults with
T1DM recognized a link between undergoing infusion therapy
and a subsequent reduction in the need for insulin injections. The
inference from this result is that whereas the general public may
consider rounds of infusion therapy to have an important impact
on their HRQL, individuals with T1DM may perceive the tran-
sitory negative impact of such a therapy as more acceptable given
the potential treatment beneﬁts. Many decision-making bodies
around the world such as NICE in the United Kingdom wish to
see utilities from the general public used in decision models. And
indeed, there has been a long-running debate regarding whether
utilities should be derived from the general public or patients.
Here is a case where it seems to make sense to at least also
Table 4 Participants’ EQ-5D rating
Dimension
Diabetic adults Diabetic adolescents Diabetic children General public
c2 (P)
(N = 51) (N = 24) (N = 20) (N = 100)
Mean SD Mean SD Mean SD Mean SD
EQ-5DVAS 78.8 16.9 80.8 14.4 80.5 162 81.7 15.9 n.s.
EQ-5D Single index 0.886 0.172 0.765 0.283 0.840 0.161 0.921 0.138 11.26 (0.010)
n.s., not signiﬁcant at 0.05 level.
Table 5 Mean utility estimates derived from mixed model (Compound Symmetry)
N
Base state utility Insulin-free utility Reduced insulin need utility On-infusion without APR On-infusion with APR
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Combined group 195 0.925 0.982 0.946 0.832 0.794
(0.908, 0.939) (0.978, 0.986) (0.933, 0.956) (0.800, 0.860) (0.756, 0.827)
General public adults 100 0.903 0.976 0.929 0.789 0.744
(0.877, 0.924) (0.969, 0.982) (0.909, 0.945) (0.741, 0.831) (0.689, 0.792)
Diabetic adults 51 0.938 0.985 0.955 0.859 0.825
(0.913, 0.956) (0.979, 0.990) (0.937, 0.968) (0.809, 0.897) (0.767, 0.871)
Combined diabetic
children & adolescents
44 0.951 0.989 0.965 0.886 0.858
(0.928, 0.967) (0.983, 0.992) (0.948, 0.976) (0.838, 0.921) (0.801, 0.901)
Diabetic adolescents 24 0.947 0.987 0.961 0.877 0.847
(0.911, 0.968) (0.979, 0.993) (0.935, 0.977) (0.805, 0.925) (0.762, 0.905)
Diabetic children 20 0.955 0.990 0.968 0.896 0.870
(0.923, 0.975) (0.982, 0.994) (0.944, 0.982) (0.827, 0.939) (0.788, 0.923)
APR, acute phase reaction; CI, conﬁdence interval.
Table 6 Mean utility estimates by participant group presented for England and Scotland separately
English participants N T1DM
T1DM
Insulin-free
T1DM reduced
insulin need On-infusion
On-infusion
with APR
Combined group 144 0.873 0.958 0.905 0.765 0.737
General public adults 72 0.853 0.950 0.889 0.740 0.693
Diabetic adults 36 0.872 0.969 0.913 0.766 0.746
Diabetic adolescents* 17 0.916 0.950 0.900 0.798 0.788
Diabetic children* 19 0.919 0.972 0.954 0.833 0.841
Scottish participants
Combined group 51 0.865 0.970 0.884 0.763 0.719
General public adults 28 0.845 0.970 0.875 0.738 0.695
Diabetic adults 15 0.882 0.981 0.892 0.777 0.725
Diabetic adolescents* 7 0.894 0.948 0.891 0.821 0.785
Diabetic children* 1 0.963 0.988 0.963 0.888 0.838
*Proxy ratings from parents.
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consider the utilities from the patients. It would be perverse to
deny a treatment to people with T1DM because the general
public considers it too burdensome when the patients themselves
do not share this view.
The design of this study incorporated the collection of utilities
from different parts of the United Kingdom to improve the rep-
resentativeness of the data. This included participants in Scotland
and England. Whereas NICE have a stated preference for utility
weights from England and Wales (or the United Kingdom), the
Scottish Medicines Consortium also have a preference for utili-
ties from Scotland. The resulting ﬁgures from the two countries
are very similar.
This study provides data that can support the development of
an economic evaluation of infusion-based therapies where ben-
eﬁts are expressed in terms of QALYs. We have provided utilities
for different important stakeholders including the general public,
adults with T1DM, and also parents. This allows the potential
beneﬁts of an infusion therapy to be considered from different
perspectives. In addition, though, we believe that the data could
also be used to support the development of patient (or even
parent) decision aids. The study collected preference data from
parents of children and adolescents and also adults with T1DM
regarding the burden of undergoing infusion therapy and also the
utility of the improvements in the need for insulin. Such data
could be incorporated into formal decision aids to help patients
and parents make decisions regarding the beneﬁts of undergoing
infusion therapy.
A number of methodological issues or limitations arose in the
course of the study. Despite numerous attempts, it was not pos-
sible to recruit the full planned sample of 50 parents of children
and adolescents with T1DM. Although the sample sizes for these
two groups are a little reduced, the utilities are broadly in line
with the other groups and so there is no reason to believe that
this has been a cause for substantial bias. Second, despite
attempts being made to recruit a representative sample of the
overall UK population, some deviation from the established soci-
etal norms was found. Although the ﬁgures suggest that the
differences are relatively small, this could be viewed as a limita-
tion of the study. Lastly, because of the inclusion of children and
adolescents, it was necessary to use parent proxy ratings of
HRQL. It may have been possible to collect self-report ratings
from the adolescents, but this was not done so that the results
were consistent with the child group. We believe one of the
strengths of this study was that speciﬁc child and adolescent
health state descriptions were produced in addition to the adult
states. Nevertheless, to collect valuation data, it was necessary to
rely on parents’ ratings. We were concerned that parents should
not think that they were being asked to value their child’s life or
to imagine that they were their child. Parents were asked to
complete the VAS and SG exercises as if they were a child of X
years of age (where X was the age of their own child). This
instruction did appear to lead individuals to “gamble” normally
but does represent a departure from typical practices. Neverthe-
less, the data and parents’ self-report suggest that they were able
to engage in this task.
Conclusions
This study presents utility values for health states relating to
infusion therapy for T1DM. The states reveal the value that the
general public and those with ﬁrsthand experience of T1DM
place on the potential burden and beneﬁts associated with such
treatment. These values are suitable for informing decision-
making generally and particularly economic evaluations where
beneﬁt is expressed in terms of quality-adjusted life-years.
Source of ﬁnancial support: A.L., and PS were both employees of Oxford
Outcomes Ltd when this project was undertaken. Oxford Outcomes were
paid a ﬁxed price by Eli Lilly to design and conduct this study. KSB, BC
and ES are employees of Eli Lilly and Company. KG has no competing
interests. BB has received grant support from Eli Lilly and Company and
Macrogenics as well as serving as a speaker’s bureau representative for Eli
Lilly and Company. SA has provided research support for clinical trials
sponsored by Eli Lilly and Company.
References
1 DCCT Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl J Med 1993;
329:977–86.
2 EDIC Group Epidemiology of diabetes interventions and compli-
cations (edic). design, implementation, and preliminary results of
a long-term follow-up of the diabetes control and complications
trial cohort. Diabetes Care 1999;22:99–111.
3 Hahl J, Hämäläinen H, Sintonen H, et al. Health-related quality
of life in type 1 diabetes without or with symptoms of long-term
complications. Qual Life Res 2002;11:427–36.
4 Brown WM. Anti-CD3 antibody Macrogenics Inc. Curr Opin
Investig Drugs 2006;7:381–8.
5 Food & Drug Administration Guidance for Industry, Diabetes
Mellitus: Developing Drugs and Therapeutics Biologics for Treat-
ment and Prevention, 2008. Available from: http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm071627.pdf [Accessed July 30, 2010].
6 Ishii, Anderson JH, Yamamura A, et al. Improvement of glycemic
control and quality-of-life by insulin lispro therapy: assessing
beneﬁts by ITR-QOL questionnaires. Diabetes Res Clin Pract
2008;81:169–78.
7 National Institute of Clinical Excellence (NICE). Guide to
Methods of Health Technology Assessment. London, UK: NICE,
2004.
8 Kostopoulou O. The transient nature of utilities and health pref-
erences. Med Decis Making 2006;26:304–6.
9 Sato E, Ohsawa I, Kataoka J, et al. Socio-psychological problem
of patients with late adolescent onset type 1 diabetes—analysis by
qualitative research. Nagoya J Med Sci 2003;66:21–9.
10 Debono M, Cachia E. The impact of diabetes on psychological
well being and quality of life. The role of patient education.
Psychol Health Med 2007;12:545–55.
11 Rendeli C, Padua L, Ausili E, et al. Quality of life in young
diabetic patients. Diabetes Nutr Metab 2003;16:251–6.
12 Hislop AL, Fegan PG, Schlaeppi MJ, et al. Prevalence and asso-
ciations of psychological distress in young adults with Type 1
diabetes. Diabet Med 2007;25:91–6.
13 Faulkner MS. Quality of life for adolescents with type 1 diabetes:
parental and youth perspectives. Pediatr Nurs 2003;29:362–8.
14 de Wit M, Delemarre-van de waal HA, Bokma JA, et al. Self-
report and parent-report of physical and psychosocial well-being
in Dutch adolescents with type 1 diabetes in relation to glycaemic
control. Health Qual Life Outcomes 2007;5:10.
15 Vanelli M, Chiarelli F, Chiari G, Tumini S. Relationship between
metabolic control and quality of life in adolescents with type 1
diabetes. Acta Biomed 2003;1:13–7.
16 Hassan K, Loar R, Anderson BJ, Heptulla RA. The role of socio-
economic status, depression, quality of life, and glycaemic control
in type 1 diabetes mellitus. J Pediatr 2006;149:526–31.
17 Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control
is associated with better quality of life in 2,101 adolescents with
type 1 diabetes. Diabetes Care 2001;23:1923–8.
18 Ausili E, Tabacco F, Focarelli B, et al. Multidimensional study on
quality of life in children with type 1 diabetes. Eur Rev Med
Pharmacol Sci 2007;11:249–55.
19 Wagner VM, Müller-Godeffroy E. Age, metabolic control and
type of insulin regime inﬂuences health-related quality of life in
children and adolescents with type 1 diabetes. Eur J Pediatr
2005;164:491–6.
Infusion Therapy Utilities for Type 1 Diabetes 641
20 Graue M, Wentzel-Larsen T, Hanestad BR, Søvik O. Health-
related quality of life and metabolic control in adolescents with
diabetes: the role of parental care, control and involvement. J
Pediatr Nurs 2005;20:373–82.
21 Weijman I, Ros WJ, Rutten GE, et al. Frequency and perceived
burden of diabetes self-management activities in employees with
insulin-treated diabetes: relationships with health outcomes. Dia-
betes Res Clin Pract 2005;68:56–64.
22 Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe
hypoglycaemia in children and adolescents with type 1 diabetes
mellitus. J Pediatr Endocrinol Metab 2005;18:83–91.
23 Joffe H, Yardley L. Content and thematic analysis. In: Marks D,
Yardley L, eds., Research Methods for Clinical and Health Psy-
chology. London: Sage, 2004.
24 Brooks R. EuroQol: the current state of play. Health Policy
1996;37:53–72.
25 Rabin R, de Charro F. EQ-5D: a measure of health status from
the EuroQol Group. Ann Med 2001;33:337–43.
26 Dolan P. Modeling valuations for EuroQoL health states. Med
Care 1997;35:1095–106.
27 Gonder-Frederick L, Cox D. Hypoglycemia Fear Survey—1998
Version. Charlotteville: University of Virginia, 1998.
28 Torrance GW. Measurement of health state utilities for economic
appraisal. J Health Econ 1986;5:1–30.
642 Lloyd et al.
